Bracco Imaging S.p.a.

Dibra S.p.a.

Bracco S.p.a.

Universita Di Pavia

Alessandro Maiocchi

Fulvio Uggeri

Simona Ghiani

Massimo Visigalli

Mario Virtuani

Luigi Miragoli

Maurizio Franzini

Luciano Lattuada

Silvio Aime

Franco Fedeli

Vittorio De Franciscis

Zsolt Baranyai

Luisella Calabi

Giovanni Valbusa

Kondareddiar Ramalingam

Pier Lucio Anelli

Ramachandran S Ranganathan

Giovanni Battista Giovenzana

Cristina Bolzati

Gyula Tircsó

Mathilde H Lerche

Pernille Rose Jensen

Magnus Karlsson

Fabio Tedoldi

Fiorenzo Refosco

Imre Tóth

Andrea Beltrami

Claudia Cabella

Zoltán Garda

Ferenc Krisztián Kálmán

Sonia Colombo Serra

Erika Reitano

Luisa Poggi

Chiara Brioschi

Lara Caminiti

Margherita Iaboni

Carla Lucia Esposito

Silvia Catuogno

Elisa Nuti

Armando Rossello

Marco Lolli

Fabrizio Rebasti

Andrea Ferraris

László Krusper

Loredana Sini

Silvia Nuzzo

Eliana Gianolio

Attilio Cesaro

Ivan Hawala

Giuseppe Ferrauto

Aldo Di Vito

Marco Crosetti

Ernö Brücher

Baranyai Zsolt

Lorena Beltrami

Stanislava Ivanova Avramova

Michele Moschetta

Raffaella Giavazzi

Simona Bussi

Barbara Spolaore

Nicola Salvarese

Ernö BRÜCHER

Ferenc Krisztián KÁLMÁN

Pietro Carretta

Marta Filibian

Elena Elisei

The present invention provides nucleic acid aptamers binding to the Carbonic Anhydrase IX (CA-IX) enzyme, derivatives and conjugates thereof and their use as diagnostic tools, particularly for the imaging of organs and tissues expressing CA-IX, or as therapeutic agents for prevention or treatment of CA-IX related diseases.

CA-IX aptamers and diagnostic and therapeutic uses thereof

The present invention refers to pharmaceutical compositions comprising a macrocyclic gadolinium complex and a water-soluble polyarylene additive useful in diagnostic imaging as diagnostic agents, in particular as contrast agents, specifically in Magnetic Resonance Imaging (MRI).

Pharmaceutical compositions comprising Gd-complexes and polyarylene additives

Disclosed are gene signatures and methods for predicting the recurrence of prostate cancer in prostatectomized subjects. Other objectives of the invention are assay devices and kits for determining the expression levels of specific gene sets correlated to prostate cancer recurrence.

Gene signatures for the prediction of prostate cancer recurrence

A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents.

Chelating AAZTA conjugates and complexes thereof

The present invention provides nucleic acid aptamers binding to the Intercellular Adhesion Molecule-1 (ICAM-1), derivatives and conjugates thereof and their use as diagnostic tools, particularly for the imaging of organs and tissues expressing ICAM-1, or as therapeutic agents for prevention or treatment of ICAM-1-related diseases.

ICAM-1 aptamers, diagnostic and therapeutic uses thereof

The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [99m Tc(N)(PNP)]-based compound suitable for a kit formulation.

Method for labeling of sensitive and thermosensitive targeting biomolecules with technetium based compounds

The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II:  d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield.

Fluorescent solid lipid nanoparticles composition and preparation thereof

The present invention relates to the use of a NIR fluorescent probe comprising an aza-bicycloalkane based cyclic peptide labelled with a Cy5.5 dye moiety in the fluorescence-guided surgery of pathologic regions and to an optical imaging method that comprises using this fluorescent probe for the identification and demarcation of tumor margins during the surgical resection.

Intra-operative imaging

The present invention relates to novel substituted ethylenediaminetetraacetic acid bisamide derivatives, their complexes with Mn(II) ion and the use thereof as contrast agents for Magnetic Resonance Imaging (MRI) analysis.

Ethylenediaminetetraacetic acid bis(amide) derivatives and their respective complexes with Mn(II) ion for use as MRI contrast agent

The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield. 

The present invention relates to paramagnetic solid lipid nanoparticles (pSLNs) comprising an amphiphilic paramagnetic metal chelating moiety selected from: a diazepine derivative of Formula I and a tetraazocyclododecane derivative of Formula (II): being said chelating moiety complexed to a paramagnetic metal ion selected from the group consisting of: Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III), Ho(III) and Er(III), or salts thereof. The invention further relates to the process for preparation of said solid lipid nanoparticles comprising amphiphilic complexes of paramagnetic metals (pSLNs) and to the use of pSLNs as MRI contrast agents in the diagnostic field.

Paramagnetic solid lipid nanoparticles (pSLNs) containing metal amphiphilic complexes for MRI

The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies.

Dynamic contrast enhanced MRI method and agents for the assessment of the macromolecular transport within pathologic tissues

The present invention generally relates to a process for the preparation of aqueous solutions of hyperpolarized molecules ready for use in in-vivo MR diagnostic imaging, the use thereof as MRI contrast agent in investigation methods for producing diagnostic MR images of a human or non-human animal body organ, region or tissue.

Process for preparing hyperpolarized substrates and method for MRI

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R, R, R, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents. 

Diagnostic agents selective against metalloproteases

The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis. The present invention refers to a new class of derivatives of formula (I), or a pharmaceutically acceptable salt thereof. 

Class of diazepine derivative chelating agents and complexes with paramagnetic metals thereof as MRI contrast agents

Growing community of inventors

Monza, Italy

Alessandro Maiocchi